_repatha-pcsk9-inhibitor-use-development-amp-very-low-ldl-levels-preview-1.jpg "Repatha: PCSK9 inhibitor USE Development & Very Low LDL Levels from pcsk Video Screenshot Preview 1")
Gallery_repatha-pcsk9-inhibitor-use-development-amp-very-low-ldl-levels-preview-3.jpg "Repatha: PCSK9 inhibitor USE Development & Very Low LDL Levels from pcsk Video Screenshot Preview 3")
Gallery_repatha-pcsk9-inhibitor-use-development-amp-very-low-ldl-levels-preview-hqdefault.jpg "Repatha: PCSK9 inhibitor USE Development & Very Low LDL Levels from pcsk Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 4 minutes 24 seconds
👁 View: 3.9K times
Play Audio:👁 View: 3.9K times
Description:
Dr. Ford Brewer MD MPH - PrevMed Health
Dr. Ford Brewer MD MPH - PrevMed Health
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_pcsk9-inhibitors-explained-in-3-minutes.webp "Drug Matters")
_the-cholesterol-wars-identifying-patients-who-would-most-benefit-from-pcsk9-inhibitors-part-1.webp "NAThrombosisForum")
⏲ 58 minutes 8 seconds 👁 346
_david-collier-clinical-director-william-harvey-clinical-research-centre-barts-amp-the-london-qmul-talks-pcsk9-amp-fourie.webp "David Collier outlines the importance of the FOURIER study in which patients at the William Harvey Clinical Research Centre have been involved. Some of their personal stories are also available on this site.nThis video was produced for the announcement of the results of the FOURIER study, funded by Amgen, in March 2017.nProduction for TrialsConnect was by Greenacre Communications – a London-based video production company specialising in health-care issues and started by John, a former patient")
⏲ 6 min 93 sec ✓ 19-Mar-2017
_oral-pcsk9-inhibitor-safety-and-efficacy-in-hypercholesterolemia-with-dr-ballantyne.webp "FITsOnTheGO")
⏲ 13 minutes 8 seconds 👁 839
_the-pcsk9-inhibitors.webp "The PCSK9 Inhibitors from pcsk")
_pcsk-feat-trill300.webp "Drøse183 - Topic")
_diagnosing-and-treating-hyperlipidemia-recent-evidence-and-the-role-of-pcsk9-targeted-therapies.webp "PeerView CME")
⏲ 53 minutes 13 seconds 👁 358
_spring-2023-ce-conference-for-the-naturopathic-community.webp "This recording is available for 6.5 Pharmacy CE Hours for Naturopathic Physicians in AZ, HI, OR, UT, and WA. The cost is $150 to access for 30 days.nn** TO RECEIVE CE HOURS FOR 2023, you must complete the quiz before Thursday 12/28/2023 **nnParticipation will be verified via a quiz, and the lecture slides are available for download after purchase. Please email us your receipt at info@communitycmpd.com after renting the video to request access to the quiz and materials. For questions or help, ple")
_pcsk9-inhibitors-explained-in-3-minutes.jpg)
_the-cholesterol-wars-identifying-patients-who-would-most-benefit-from-pcsk9-inhibitors-part-1.jpg)
_david-collier-clinical-director-william-harvey-clinical-research-centre-barts-amp-the-london-qmul-talks-pcsk9-amp-fourie.jpg)
_oral-pcsk9-inhibitor-safety-and-efficacy-in-hypercholesterolemia-with-dr-ballantyne.jpg)
_the-pcsk9-inhibitors.jpg)
_pcsk-feat-trill300.jpg)
_diagnosing-and-treating-hyperlipidemia-recent-evidence-and-the-role-of-pcsk9-targeted-therapies.jpg)
_spring-2023-ce-conference-for-the-naturopathic-community.jpg)
![[+]](/images/menu.gif){kind=small}